GlaxoSmithKline Pharmaceuticals (GSK) has launched Shingrix (zoster vaccine recombinant, adjuvanted) in India, for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above. Shingrix is a non-live, recombinant subunit vaccine to be given intramuscularly in two doses. Shingles are caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. A seroprevalence study in Indian subjects showed that by the age of 40 years more than 90 per cent had this virus in their body and were vulnerable to shingles. Shingles cause a painful rash. In all cases, the rash disappears, but in a large number of cases, the pain persists for months or years. This pain is known as post-herpetic neuralgia (PHN). Bhushan Akshikar, MD, GSK says,
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!